New data finds an experimental cancer treatment is showing major promise. Our team spoke with the first person to receive a ...

Nearly all of the patients who responded to the a personalized mRNA pancreatic vaccine are still alive six years later.

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

The 16th Annual Lustgarten Foundation New York City Walk for Pancreatic Cancer Research was held Sunday in Battery Park City.

New experimental medications seem to extend survival with the hard-to-treat cancer.

A new drug that works by making tumors more susceptible to chemotherapy and the immune system has increased survival in those ...

Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna ...

This week on "The Readout LOUD," a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.

In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...

We are once again proud to join the Lustgarten Foundation in raising awareness and funds for critical pancreatic cancer ...